Faculty

Back to Index
Mark Floyd Lew, MD
Professor of Clinical Neurology
Joseph P. Van Der Meulen, M.D. Chair in Parkinson's Disease Research in Honor of Robert J. Pasarow
Vice Chair, Department of Neurology
Division Chief, Movement Disorders
Neurology
HCC 3000 1520 San Pablo Street Health Sciences Campus Los Angeles
+1 323 442 5728

Overview

Dr. Lew has an international reputation for the treatment of patients with Parkinson’s disease, dystonia, and other movement disorders. He is a board certified neurologist and a fellow of the American Academy of Neurology. Dr. Lew is the director of the Division of Movement Disorders and serves as the vice chairman of the Department of Neurology. He has lectured extensively in the United States and abroad on clinical research related to new therapies for Parkinson’s disease and dystonia. Dr. Lew also collaborates closely with local and national advocacy organizations (e.g., the Hollyrod Foundation and the National Parkinson’s Foundation) to increase public awareness and to support research and care.

Publications

The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. J Neurol. 2017 Aug; 264(8):1567-1582. View in: PubMed

Differential diagnosis of suspected neurogenic orthostatic hypotension in a patient with Parkinson disease. Clin Auton Res. 2017 Jul; 27(Suppl 1):5-7. View in: PubMed

Initiating droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease. Clin Auton Res. 2017 Jul; 27(Suppl 1):13-14. View in: PubMed

Adding droxidopa to fludrocortisone or midodrine in a patient with neurogenic orthostatic hypotension and Parkinson disease. Clin Auton Res. 2017 Jul; 27(Suppl 1):29-31. View in: PubMed

Managing supine hypertension in a patient with non-diabetic autonomic neuropathy receiving droxidopa for neurogenic orthostatic hypotension. Clin Auton Res. 2017 Jul; 27(Suppl 1):35-37. View in: PubMed

Clinical utility of DaTscan™ imaging in the evaluation of patients with parkinsonism: a US perspective. Expert Rev Neurother. 2017 Mar; 17(3):219-225. View in: PubMed

The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. J Neurol. 2017 Jan 03. View in: PubMed

Apomorphine Subcutaneous Injection for the Management of Morning Akinesia in Parkinson's Disease. Mov Disord Clin Pract. 2017 Jan-Feb; 4(1):78-83. View in: PubMed

RimabotulinumtoxinB in sialorrhea: systematic review of clinical trials. J Clin Mov Disord. 2017; 4:9. View in: PubMed

Clinical utility of DaTscan™ imaging in the evaluation of patients with parkinsonism: a US perspective. Expert Rev Neurother. 2016 Nov 23; 1-7. View in: PubMed

A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease. Mov Disord. 2016 Sep; 31(9):1373-80. View in: PubMed

Poster 290 Efficacy and Safety of a 2 mL Dilution of AbobotulinumtoxinA Compared with Placebo in Adult Patients with Cervical Dystonia. PM R. 2016 Sep; 8(9S):S254-S255. View in: PubMed

Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials. Mov Disord. 2016 Apr; 31(4):538-46. View in: PubMed

Initiation and dose optimization for levodopa-carbidopa intestinal gel: Insights from phase 3 clinical trials. Parkinsonism Relat Disord. 2015 Jul; 21(7):742-8. View in: PubMed

Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results. Mov Disord. 2015 Apr; 30(4):500-9. View in: PubMed

Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA. 2015 Feb 10; 313(6):584-93. View in: PubMed

Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol. 2014 Aug; 13(8):767-76. View in: PubMed

A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol. 2014 May; 71(5):543-52. View in: PubMed

A randomized clinical trial of high-dosage coenzyme q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol. 2014 May 1; 71(5):543-52. View in: PubMed

Rasagiline treatment effects on parkinsonian tremor. Int J Neurosci. 2013 Dec; 123(12):859-65. View in: PubMed

Immunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: report of 4 prospective, multicenter trials. Clin Neuropharmacol. 2012 Sep; 35(5):215-23. View in: PubMed

Immunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: report of 4 prospective, multicenter trials. Clin Neuropharmacol. 2012 Sep-Oct; 35(5):215-23. View in: PubMed

Accuracy and sensitivity of Parkinsonian disorder diagnoses in two Swedish national health registers. Neuroepidemiology. 2012; 38(3):186-93. View in: PubMed

Immediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: effects on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing off. Int J Neurosci. 2011 Nov; 121(11):605-13. View in: PubMed

Long-term, open-label study of once-daily ropinirole prolonged release in early Parkinson's disease. Int J Neurosci. 2011 May; 121(5):246-53. View in: PubMed

The evidence for disease modification in Parkinson's disease. Int J Neurosci. 2011; 121 Suppl 2:18-26. View in: PubMed

Polycythemia and chorea. Handb Clin Neurol. 2011; 100:271-6. View in: PubMed

Long-term efficacy of rasagiline in early Parkinson's disease. Int J Neurosci. 2010 Jun; 120(6):404-8. View in: PubMed

Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord. 2010 Jun; 16(5):316-23. View in: PubMed

RimabotulinumtoxinB effects on pain associated with cervical dystonia: results of placebo and comparator-controlled studies. Int J Neurosci. 2010 Apr; 120(4):298-300. View in: PubMed

Increased melanoma risk in Parkinson disease: a prospective clinicopathological study. Arch Neurol. 2010 Mar; 67(3):347-52. View in: PubMed

Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects. Clin Neuropharmacol. 2010 Jan-Feb; 33(1):5-10. View in: PubMed

Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov Disord. 2009 Mar 15; 24(4):564-73. View in: PubMed

Complete ascertainment of Parkinson disease in the Swedish Twin Registry. Neurobiol Aging. 2008 Dec; 29(12):1765-73. View in: PubMed

The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study. BMC Med. 2008 Nov 05; 6:32. View in: PubMed

Huntington CAG repeat size does not modify onset age in familial Parkinson's disease: the GenePD study. Mov Disord. 2008 Aug 15; 23(11):1596-601. View in: PubMed

Replication of association between ELAVL4 and Parkinson disease: the GenePD study. Hum Genet. 2008 Aug; 124(1):95-9. View in: PubMed

Role of botulinum toxin in the treatment of cervical dystonia. Neurol Clin. 2008 May; 26 Suppl 1:43-53. View in: PubMed

The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study. BMC Med. 2008; 6:32. View in: PubMed

Overview of Parkinson's disease. Pharmacotherapy. 2007 Dec; 27(12 Pt 2):155S-160S. View in: PubMed

Results from a 2-year centralized tolcapone liver enzyme monitoring program. Clin Neuropharmacol. 2007 Sep-Oct; 30(5):281-6. View in: PubMed

Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of 'off' episodes in patients with Parkinson's disease. Curr Med Res Opin. 2007 Apr; 23(4):741-50. View in: PubMed

Calcification of the Basal Ganglia. Handb Clin Neurol. 2007; 84:479-86. View in: PubMed

Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study. Arch Neurol. 2006 Jun; 63(6):826-32. View in: PubMed

Selegiline orally disintegrating tablets for the treatment of Parkinson's disease. Expert Rev Neurother. 2005 Nov; 5(6):705-12. View in: PubMed

Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord. 2005 Jul; 20(7):783-91. View in: PubMed

Behavioral changes as side effects of medication treatment for Parkinson's disease. Adv Neurol. 2005; 96:114-29. View in: PubMed

Duration of effectiveness of botulinum toxin type B in the treatment of cervical dystonia. Adv Neurol. 2004; 94:211-5. View in: PubMed

Gait and Balance Dysfunction in Adults. Curr Treat Options Neurol. 2003 Mar; 5(2):177-185. View in: PubMed

Review of the FDA-approved uses of botulinum toxins, including data suggesting efficacy in pain reduction. Clin J Pain. 2002 Nov-Dec; 18(6 Suppl):S142-6. View in: PubMed

Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002 Oct; 59(10):1541-50. View in: PubMed

PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD study. Am J Hum Genet. 2002 May; 70(5):1089-95. View in: PubMed

Botulinum toxin type B: An effective treatment for alleviating pain associated with cervical dystonia. J Back Musculoskelet Rehabil. 2002 Jan 01; 16(1):3-9. View in: PubMed

Botulinum toxin type B: An effective treatment for alleviating pain associated with cervical dystonia. J Back Musculoskelet Rehabil. 2002 Jan 1; 16(1):3-9. View in: PubMed

Botulinum toxin type B (Myobloc, NeuroBloc): a new choice in cervical dystonia. Expert Rev Neurother. 2001 Nov; 1(2):143-52. View in: PubMed

Powered bySC CTSI